Mylan Partially Beats Amgen Neulasta Biosimilar Claims
In light of a recent Federal Circuit decision, Amgen Inc. can no longer allege that Mylan Inc.'s proposed Neulasta biosimilar infringed one of its patents, a Pennsylvania federal court ruled Wednesday,...To view the full article, register now.
Already a subscriber? Click here to view full article